Description
Product Usage Information
Western Blotting: 1:1000
Immunohistochemistry (Paraffin): 1:100
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Western Blotting, Immunohistochemistry (Paraffin)
Specificity / Sensitivity
EMR2 (F7F6M) Rabbit Monoclonal Antibody recognizes endogenous levels of total EMR2 protein. This antibody does not cross-react with EMR1 or CD97 protein.
Species Reactivity: Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly440 of human EMR2 protein.
Background
Epidermal growth factor (EGF) module-containing mucin-like receptor 2 (EMR2), also known as CD312 or adhesion G protein-coupled receptor E2 (ADGRE2), is a member of the adhesion G protein-coupled receptor (ADGRE) family (also referred to as the EGF-TM7 family). This family is a unique class of receptors characterized by a large N-terminal extracellular region containing multiple tandem EGF-like domains, a mucin-like stalk, and a seven-transmembrane domain typical of GPCRs. Similar to other family members, EMR2 plays a functional role in cellular adhesion, migration, and signaling (1). EMR2 is closely related to CD97, also known as ADGRE5, and is likely the product of a gene duplication event; however, EMR2 cannot bind the CD55 ligand that readily binds CD97 (2). EMR2 expression is also restricted to myeloid cells, whereas CD97 expression is relatively ubiquitous (2). EMR2 has been shown to promote differentiation and cytokine release in human macrophages, as well as adhesion, chemotaxis, and degranulation in neutrophils (3-5). EMR2 also contributes to pediatric acute lymphoblastic leukemia (ALL) by promoting an immunosuppressive environment, and its upregulation is associated with poor survival in glioblastoma (GBM) and acute myeloid leukemia (AML) (6,7). Recent studies have shown promise in targeting EMR2 with chimeric antigen receptor T cell (CAR-T) therapy to treat AML patients (8).Â
Alternate Names
ADGRE2; Adhesion G protein-coupled receptor E2; AGRE2; CD312; CD97; CD97 antigen; egf-like module containing, mucin-like, hormone receptor-like 2; EGF-like module receptor 2; EGF-like module-containing mucin-like hormone receptor-like 2; EMR2; Leukocyte antigen CD97; VBU
